Inhibitors of the rate-limiting enzyme of bilirubin formation are being studied in normal adults and in patients with hepatic dysfunction. The agents, Sn-protoporphyrin and Sn-mesoporphyrin are potent competitors of heme oxygenase, and have now been shown to decrease bilirubin production and plasma and biliary bilirubin levels in a number of animal models and in humans. The compounds are remarkably nontoxic and are expected to be useful for ameliorating neonatal jaundice, thereby diminishing the risk of bilirubin CNS toxicity.
Showing the most recent 10 out of 461 publications